Vericel Stock Forecast
NASDAQ: VCELHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
VCEL analyst consensus
Consensus (8 analysts)
none
Avg. price target
$60.57+48.67%
- Strong buy 0
- Buy 7
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 8 Wall Street analysts covering Vericel (2026-10-07), 7 rate the stock a buy or strong buy, 1 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "none". The average 12-month price target is $60.57, with a high estimate of $72.00 and a low estimate of $55.00. The average target implies upside of 48.7% from the current price of $40.74.
The spread between the highest and lowest targets is 30.9%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for VCEL.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 7 | 88% |
| Hold | 1 | 13% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $55.00 | +35.00% |
| Average target | $60.57 | +48.67% |
| High target | $72.00 | +76.73% |